119 related articles for article (PubMed ID: 15193294)
21. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
Lindgren HS; Ohlin KE; Cenci MA
Neuropsychopharmacology; 2009 Nov; 34(12):2477-88. PubMed ID: 19606087
[TBL] [Abstract][Full Text] [Related]
22. Effects of full D1 dopamine receptor agonists on firing rates in the globus pallidus and substantia nigra pars compacta in vivo: tests for D1 receptor selectivity and comparisons to the partial agonist SKF 38393.
Ruskin DN; Rawji SS; Walters JR
J Pharmacol Exp Ther; 1998 Jul; 286(1):272-81. PubMed ID: 9655869
[TBL] [Abstract][Full Text] [Related]
23. Role of the superior colliculus in the motor effects of cannabinoids and dopamine.
Sañudo-Peña MC; Tsou K; Romero J; Mackie K; Walker JM
Brain Res; 2000 Jan; 853(2):207-14. PubMed ID: 10640618
[TBL] [Abstract][Full Text] [Related]
24. L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus.
Bonaventura J; Rico AJ; Moreno E; Sierra S; Sánchez M; Luquin N; Farré D; Müller CE; Martínez-Pinilla E; Cortés A; Mallol J; Armentero MT; Pinna A; Canela EI; Lluís C; McCormick PJ; Lanciego JL; Casadó V; Franco R
Neuropharmacology; 2014 Apr; 79():90-100. PubMed ID: 24230991
[TBL] [Abstract][Full Text] [Related]
25. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
[TBL] [Abstract][Full Text] [Related]
26. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
[TBL] [Abstract][Full Text] [Related]
27. Subthalamic high frequency stimulation induced rotations are differentially mediated by D1 and D2 receptors.
Bergmann O; Winter C; Meissner W; Harnack D; Kupsch A; Morgenstern R; Reum T
Neuropharmacology; 2004 Jun; 46(7):974-83. PubMed ID: 15081794
[TBL] [Abstract][Full Text] [Related]
28. Intrastriatal dopamine D1 receptor agonist-mediated motor behavior is reduced by local neurokinin 1 receptor antagonism.
Krolewski DM; Bishop C; Walker PD
Synapse; 2005 Jul; 57(1):1-7. PubMed ID: 15858838
[TBL] [Abstract][Full Text] [Related]
29. Striatal NTS1 , dopamine D2 and NMDA receptor regulation of pallidal GABA and glutamate release--a dual-probe microdialysis study in the intranigral 6-hydroxydopamine unilaterally lesioned rat.
Ferraro L; O'Connor WT; Beggiato S; Tomasini MC; Fuxe K; Tanganelli S; Antonelli T
Eur J Neurosci; 2012 Jan; 35(2):207-20. PubMed ID: 22211865
[TBL] [Abstract][Full Text] [Related]
30. An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.
Jones CA; Johnston LC; Jackson MJ; Smith LA; van Scharrenburg G; Rose S; Jenner PG; McCreary AC
Eur Neuropsychopharmacol; 2010 Aug; 20(8):582-93. PubMed ID: 20434890
[TBL] [Abstract][Full Text] [Related]
31. Opposite function of dopamine D1 and N-methyl-D-aspartate receptors in striatal cannabinoid-mediated signaling.
Daigle TL; Wetsel WC; Caron MG
Eur J Neurosci; 2011 Nov; 34(9):1378-89. PubMed ID: 22034973
[TBL] [Abstract][Full Text] [Related]
32. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Van De Witte SV; Groenewegen HJ; Voorn P
Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
[TBL] [Abstract][Full Text] [Related]
33. D(2), but not D(1) dopamine receptor agonists potentiate cannabinoid-induced sedation in nonhuman primates.
Meschler JP; Clarkson FA; Mathews PJ; Howlett AC; Madras BK
J Pharmacol Exp Ther; 2000 Mar; 292(3):952-9. PubMed ID: 10688609
[TBL] [Abstract][Full Text] [Related]
34. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum.
Giuffrida A; Parsons LH; Kerr TM; Rodríguez de Fonseca F; Navarro M; Piomelli D
Nat Neurosci; 1999 Apr; 2(4):358-63. PubMed ID: 10204543
[TBL] [Abstract][Full Text] [Related]
35. The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization.
Thiemann G; van der Stelt M; Petrosino S; Molleman A; Di Marzo V; Hasenöhrl RU
Behav Brain Res; 2008 Mar; 187(2):289-96. PubMed ID: 17988751
[TBL] [Abstract][Full Text] [Related]
36. Cannabinoid-induced depression of synaptic transmission is switched to stimulation when dopaminergic tone is increased in the globus pallidus of the rodent.
Caballero-Florán RN; Conde-Rojas I; Oviedo Chávez A; Cortes-Calleja H; Lopez-Santiago LF; Isom LL; Aceves J; Erlij D; Florán B
Neuropharmacology; 2016 Nov; 110(Pt A):407-418. PubMed ID: 27506997
[TBL] [Abstract][Full Text] [Related]
37. Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice.
González S; Mena MA; Lastres-Becker I; Serrano A; de Yébenes JG; Ramos JA; Fernández-Ruiz J
Brain Res; 2005 Jun; 1046(1-2):195-206. PubMed ID: 15882845
[TBL] [Abstract][Full Text] [Related]
38. Modulation of endogenous GABA release by an antagonistic adenosine A1/dopamineD1 receptor interaction in rat brain limbic regions but not basal ganglia.
Mayfield RD; Jones BA; Miller HA; Simosky JK; Larson GA; Zahniser NR
Synapse; 1999 Sep; 33(4):274-81. PubMed ID: 10421708
[TBL] [Abstract][Full Text] [Related]
39. GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat.
Petri D; Pum M; Vesper J; Huston JP; Schnitzler A
Behav Brain Res; 2013 Sep; 252():58-67. PubMed ID: 23727148
[TBL] [Abstract][Full Text] [Related]
40. Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents.
Wade MR; Degroot A; Nomikos GG
Eur J Pharmacol; 2006 Dec; 551(1-3):162-7. PubMed ID: 17030030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
